Update on the State of Vaccines for Melanoma
Introduction Scientists have recently advanced a strategy to send human cells instructions to generate an immune response against cancer. It…
Melanoma Research
04/15/2025
Update on the State of Vaccines for Melanoma
Introduction Scientists have recently advanced a strategy to send human cells instructions to generate an immune response against cancer. It…
|
02/06/2025
Genetic Testing Performed in Melanoma
A Q&A with an Investigator at the National Institutes of Health Dr. Michael Sargen M.D. is an Assistant Clinical Investigator…
|
12/27/2024
Bristol Myers Squibb Announces Approval for Subcutaneous Nivolumab
The Food and Drug Administration approval provides another option for cancer patients December 27, 2024 (Sacramento, California) The FDA has…
|
|
10/17/2024
In Plain English: Update on Melanoma Vaccines, 2024
By Kim Margolin, M.D., FACP, FASCO Recap and background on tumor vaccines We last visited the topic of vaccines in…
|
|
09/20/2024
Recurrence Rate of Small Melanoma In Situ on Low-Risk Sites Excised With 5-mm Excisional Margin
How much is enough? Exploring excisional margins for in situ melanoma When a patient with melanoma in situ has a…
|
09/15/2024
Long-term Results Continue to Show a Benefit with Nivolumab and Ipilimumab
There is good news for patients with melanoma who received immunotherapy. Survival results from a major clinical trial, CheckMate-067, show…
|
09/15/2024
Ten Years of Pembrolizumab Shows Sustained Results
There is good news for patients with advanced melanoma who received pembrolizumab. Results from a clinical trial after ten years…
|
09/15/2024
Oncolytic Virotherapy Shows Promise in Advanced Melanoma that Failed Immunotherapy
New clinical trial data shows that additional options may soon become available for patients with melanoma for whom immunotherapy did…
|
09/15/2024
New Therapies Under Investigation for Patients With Metastatic Uveal Melanoma
Results from a Phase 2 clinical trial for patients with advanced uveal melanoma were presented at ESMO 2024 on September…
|
09/14/2024
News from ESMO: NADINA Trial Update in Stage III Melanoma
A follow-up report with data from NADINA was presented at the European Society for Medical Oncology (ESMO) Congress on September…
|
